Biomarkers for Epithelial Cancer Diagnosis and Treatment

摘要

Disclosed herein are methods for diagnosing the state of an epithelial tumor or tissue in a subject. Also disclosed are methods of diagnosing tumor initiation in an epithelial tissue of a subject. Also disclosed are methods of determining prognosis of a subject with an epithelial tumor. These methods include, in part, measuring the amount of pSer239-VASP, pSer157-VASP, and/or total VASP in a subject or in a tissue or tumor of a subject and comparing those levels to an appropriate reference level. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention

主权项

1. A method for treating a patient who has an epithelial tumor, the method comprising the steps of:
A) identifying the patient as having a poor prognosis by
i) a) measuring the level of pSer239-VASP in a sample of the tumor to establish a tumor pSer239-VASP level,
b) measuring the level of total VASP in a sample of the tumor to establish a tumor total-VASP level;c) calculating relative amounts of the tumor pSer239-VASP and tumor total-VASP as ratio tumor pSer239-VASP:tumor total-VASP, andd) comparing the ratio tumor pSer239-VASP:tumor total-VASP to that of an appropriate control, wherein a reduction in the ratio pSer239-VASP:tumor total VASP compared to the appropriate control indicates a negative prognosis; and/orii) a) measuring the level of pSer157-VASP in a sample of the tumor to establish a tumor pSer157-VASP level,
b) measuring the level of total VASP in a sample of the tumor to establish a tumor total-VASP level;c) calculating relative amounts of the tumor pSer157-VASP and tumor total-VASP as ratio tumor pSer157-VASP:tumor total-VASP, andd) comparing the ratio tumor pSer157-VASP:tumor total-VASP to that of an appropriate control, wherein a reduction in the ratio pSer157-VASP:tumor total VASP compared to the appropriate control indicates a negative prognosis; and/oriii) a) measuring the level of pSer157-VASP in a sample of the tumor to establish a tumor pSer157-VASP level,
b) measuring the level of pSer157-VASP in a sample of normal tissue adjacent to the tumor to establish a normal pSer157-VASP level, andc) calculating relative amounts of the tumor pSer157-VASP and normal pSer157-VASP level as ratio tumor pSer157-VASP:normal pSer157-VASP, andd) comparing the ratio tumor pSer157-VASP:normal pSer157-VASP to that of an appropriate control, wherein a reduced relative amount of tumor pSer157-VASP:normal pSer157-VASP compared to the appropriate control indicates a negative prognosis; and/oriv) a) measuring the level of pSer239-VASP in a sample of the tumor to establish a tumor pSer239-VASP level,
b) measuring the level of pSer239-VASP in a sample of normal tissue adjacent to the tumor to establish a normal pSer239-VASP level, andc) calculating relative amounts of the tumor pSer239-VASP and normal pSer239-VASP level as ratio tumor pSer239-VASP:normal pSer239-VASP, andd) comparing the ratio tumor pSer239-VASP:normal pSer239-VASP to that of an appropriate control, wherein a reduction in the ratio tumor pSer239-VASP:normal pSer239-VASP compared to the appropriate control indicates a negative prognosis; and/orv) a) measuring the level of pSer239-VASP in a sample of the tumor to establish a tumor pSer239-VASP level,
b) measuring the level of pSer157-VASP in a sample of the tumor to establish a tumor pSer157-VASP level,c) calculating relative amounts of the tumor pSer239-VASP and tumor pSer157-VASP as ratio tumor pSer239-VASP:tumor pSer157-VASP, andd) comparing the ratio tumor pSer239-VASP:tumor pSer157-VASP to that of an appropriate control, wherein a reduction in the ratio tumor pSer239-VASP:tumor pSer157-VASP compared to the appropriate control indicates a negative prognosis; and B) treating the patient identified as having a negative prognosis using chemotherapy and/or radiation therapy.